Henlius Biotech Advances Toward Privatisation

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.

Shanghai Henlius Biotech, Inc. is actively working towards the fulfillment of pre-conditions for its proposed merger by absorption with Fosun New Medicine, which includes regulatory approvals and filings with Chinese authorities. However, the despatch of the Composite Document detailing the merger’s revised proposal and related matters has been delayed. This action is part of the preconditional privatisation and intended withdrawal of Henlius Biotech’s listing on the stock exchange.

For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.